



#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: RAMNARAYAN *et al.*  
Serial No.: 09/709,905  
Filed: November 10, 2000  
For: *USE OF COMPUTATIONALLY DERIVED  
PROTEIN STRUCTURES OF GENETIC  
POLYMORPHISMS IN PHARMACOGENOMICS  
FOR DRUG DESIGN AND CLINICAL  
APPLICATIONS;*  
Art Unit: Unassigned  
Examiner: Unassigned

I hereby certify that this paper and the attached  
papers are being deposited with the United States  
Postal Service as first class mail in an envelope  
addressed to:  
Commissioner for Patents  
Washington, D.C. 20231 on this date

02/21/01  
Date

Shelley M. Callagy

#3  
4/27/02

INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE  
WITH 37 C.F.R. §§ 1.97-1.98

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Since this Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§ 1.97-1.98. The Forms PTO-1449 (10 pages) are provided herewith. In accordance with 37 C.F.R. § 1.98(d), copies of the references marked with an asterisk on the Form PTO-1449 are not provided herewith, as they have been previously provided in connection with application U.S. Serial Nos. 09/438,566 and 09/704,362, which are relied upon for an earlier filing date in accordance with 35 U.S.C. § 120.

The documents listed on the Forms PTO-1449 and supplied herewith are in the English language. Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

**U.S.S.N. 09/709,905**  
**RAMNARAYAN, *et al.***  
**IDS**

Applicant also makes known to the Examiner the following U.S. applications which are commonly owned and/or have one or more inventors in common.

<u>U.S.S.N.(App. no.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
09/272,814	03/19/99	1904
09/531,995	03/20/00	1904B
09/438,566	11/10/99	1906
09/704,362	11/01/00	1906B

  

<u>U.S.S.N.(App. no.)</u>	<u>Filing Date</u>	<u>Docket No.</u>
PCT/US00/30863	11/10/00	1906PC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. § 1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. § 1.56(b) exists.

Pursuant to 37 C.F.R. § 1.56, if inventors of subject matter not commonly owned at the time of the later invention file a joint application (i.e. the above-mentioned continuation-in-part application), applicant has an obligation to point this out.

The above-captioned application, which is a continuation-in-part (CIP) of patent application U.S. Serial No. 09/704,362, which is a continuation of patent application US Serial No. 09/438,566, designates as joint inventors: Kal Ramnarayan, Edward T. Maggio, and Pat Hess. This CIP application makes of record two assignees: (1) Structural Bioinformatics, Inc. for the joint inventors Kal Ramnarayan and Edward T. Maggio and (2) Quest Diagnostics, Inc. for the joint inventor Pat Hess.

**U.S.S.N. 09/709,905**  
**RAMNARAYAN, *et al.***  
**IDS**

Applicant respectfully requests that the Examiner review the foregoing reference and information and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,  
HELLER EHRMAN WHITE & MCAULIFFE LLP

By:   
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 24737-1906C  
**Address all correspondence to:**  
Heller Ehrman White & McAuliffe LLP  
4250 Executive Square, 7th Floor  
La Jolla, California 92037-9103  
Telephone: (858) 450-8400  
Facsimile: (858) 587-5360  
EMAIL sseidman@HEWM.com